2C-T-13

2C-T-13 (2,5-dimethoxy-4-(β-methoxyethylthio)phenethylamine) is a psychedelic phenethylamine of the 2C family. It was presumably first synthesized by Alexander Shulgin and reported in his book PiHKAL.[1]

2C-T-13
Names
Preferred IUPAC name
2-{2,5-Dimethoxy-4-[(2-methoxyethyl)sulfanyl]phenyl}ethan-1-amine
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
PubChem CID
UNII
InChI
  • InChI=1S/C13H21NO3S/c1-15-6-7-18-13-9-11(16-2)10(4-5-14)8-12(13)17-3/h8-9H,4-7,14H2,1-3H3 Y
    Key: PYJLRNOGMKMRTK-UHFFFAOYSA-N Y
  • InChI=1/C13H21NO3S/c1-15-6-7-18-13-9-11(16-2)10(4-5-14)8-12(13)17-3/h8-9H,4-7,14H2,1-3H3
    Key: PYJLRNOGMKMRTK-UHFFFAOYAS
SMILES
  • COc1cc(SCCOC)c(cc1CCN)OC
Properties
Chemical formula
C13H21NO3S
Molar mass 271.38 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

Chemistry

The drug has structural properties similar to mescaline and other drugs in the 2C-T series, with the most closely related compounds being 2C-T-7 and 2C-T-21.

General information

The dosage range of 2C-T-13 is typically 25 - 40 mg and its duration is approximately 6–8 hours according to Shulgin.[1] 2C-T-13 produces many closed-eye visuals and geometric patterns. It also produces slight visual distortion.[1]

Pharmacology

The mechanism that produces 2C-T-13's hallucinogenic and entheogenic effects has not been specifically established; however, it is most likely to result from action as a 5-HT2A serotonin receptor agonist in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines for which the mechanism of action is known.

Dangers

The toxicity of 2C-T-13 is not well documented. 2C-T-13 is slightly less potent than 2C-T-7, but it may be expected that at higher doses it would display similar toxicity to that of other phenethylamines of the 2C-T family.

Legality

2C-T-13 is not scheduled in the United States, but possession and sales of 2C-T-13 could be prosecuted under the Federal Analog Act because of its structural similarities to 2C-T-7.

As of October 31, 2016, 2C-T-13 is a controlled substance (Schedule III) in Canada.[2]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.